. A Korean biopharmaceutical company is facing an ICC lodged by its Chinese partner in a US$81 million collaboration to develop a treatment for autoimmune diseases – and says it has filed a counterclaim to terminate the partnership
. A Korean biopharmaceutical company is facing an ICC lodged by its Chinese partner in a US$81 million collaboration to develop a treatment for autoimmune diseases – and says it has filed a counterclaim to terminate the partnership